Vinblastine monotherapy induction prior to radiotherapy for patients with intracranial germinoma during the COVID-19 pandemic.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Brain Neoplasms
/ drug therapy
COVID-19
Carboplatin
/ therapeutic use
Child
Etoposide
/ therapeutic use
Female
Germinoma
/ drug therapy
Humans
Male
Neoplasms, Germ Cell and Embryonal
/ drug therapy
Pandemics
Vinblastine
/ therapeutic use
carboPEI
carboplatin
germinoma
intracranial
monotherapy
vinblastine
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
02
09
2021
received:
30
06
2021
accepted:
05
09
2021
pubmed:
15
9
2021
medline:
24
12
2021
entrez:
14
9
2021
Statut:
ppublish
Résumé
Patients with localized intracranial germinoma have excellent survival. Reducing treatment burden and long-term sequelae is a priority. Intensive inpatient chemotherapy (e.g., carboPEI = carboplatin/etoposide/ifosfamide) has been effectively employed to reduce radiotherapy treatment volume/dose. Outpatient-based carboplatin monotherapy is associated with excellent outcomes in metastatic testicular seminoma (an identical pathology), and successful vinblastine monotherapy induction (with 77% tumor volume reduction after just two weekly vinblastine doses) has recently been reported in an intracranial germinoma patient. Adapted UK guidelines for germ cell tumor management were distributed during the COVID-19 pandemic, including nonstandard treatment options to reduce hospital visits and/or admissions. This included vinblastine monotherapy for intracranial germinoma (6 mg/m A 30-year-old male with a localized pineal tumor received 12-week vinblastine induction, with >60% volume reduction, prior to definitive radiotherapy. A 12-year-old female with a metastatic suprasellar tumor and progression at all sites of disease whilst awaiting proton radiotherapy received two vinblastine doses with good early response, including 36% primary tumor volume reduction. The patients tolerated vinblastine well. Patients with intracranial germinoma have excellent outcomes, and reduction of late effects remains a priority. The description of vinblastine monotherapy in these intracranial germinoma patients warrants further exploration.
Sections du résumé
BACKGROUND
Patients with localized intracranial germinoma have excellent survival. Reducing treatment burden and long-term sequelae is a priority. Intensive inpatient chemotherapy (e.g., carboPEI = carboplatin/etoposide/ifosfamide) has been effectively employed to reduce radiotherapy treatment volume/dose. Outpatient-based carboplatin monotherapy is associated with excellent outcomes in metastatic testicular seminoma (an identical pathology), and successful vinblastine monotherapy induction (with 77% tumor volume reduction after just two weekly vinblastine doses) has recently been reported in an intracranial germinoma patient.
METHODS
Adapted UK guidelines for germ cell tumor management were distributed during the COVID-19 pandemic, including nonstandard treatment options to reduce hospital visits and/or admissions. This included vinblastine monotherapy for intracranial germinoma (6 mg/m
RESULTS
A 30-year-old male with a localized pineal tumor received 12-week vinblastine induction, with >60% volume reduction, prior to definitive radiotherapy. A 12-year-old female with a metastatic suprasellar tumor and progression at all sites of disease whilst awaiting proton radiotherapy received two vinblastine doses with good early response, including 36% primary tumor volume reduction. The patients tolerated vinblastine well.
CONCLUSION
Patients with intracranial germinoma have excellent outcomes, and reduction of late effects remains a priority. The description of vinblastine monotherapy in these intracranial germinoma patients warrants further exploration.
Identifiants
pubmed: 34520101
doi: 10.1002/pbc.29359
pmc: PMC8662027
doi:
Substances chimiques
Vinblastine
5V9KLZ54CY
Etoposide
6PLQ3CP4P3
Carboplatin
BG3F62OND5
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29359Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Reprod Sci. 2021 Feb;28(2):603-613
pubmed: 33150486
Neuro Oncol. 2013 Jun;15(6):788-96
pubmed: 23460321
Pediatr Blood Cancer. 2010 Jul 15;55(1):42-6
pubmed: 20222020
J Neurooncol. 2020 Sep;149(3):523-532
pubmed: 33034840
Int J Cancer. 2017 Aug 1;141(3):621-635
pubmed: 28463397
Thromb Haemost. 2021 May;121(5):625-640
pubmed: 33186995
Pediatr Blood Cancer. 2008 Feb;50(2):347-51
pubmed: 17973323
J Pediatr Surg. 2019 Sep;54(9):1894-1900
pubmed: 30415957
Orphanet J Rare Dis. 2011 Dec 12;6:83
pubmed: 22151964
Gan No Rinsho. 1986 Sep;32(11):1387-93
pubmed: 2430119
Cancer. 1994 Aug 1;74(3):940-4
pubmed: 8039122
Eur J Cancer. 2020 Oct 8;:
pubmed: 33041185
Acta Neuropathol. 2016 Jun;131(6):889-901
pubmed: 26956871
J Clin Oncol. 2016 Oct 10;34(29):3537-3543
pubmed: 27573663
JAMA Oncol. 2016 Dec 1;2(12):1624-1627
pubmed: 27711914
Radiology. 1978 Sep;128(3):745-51
pubmed: 674649
J Neurooncol. 2010 May;97(3):393-9
pubmed: 19820898
Br J Cancer. 1999 Mar;79(7-8):1199-204
pubmed: 10098759
Pediatr Blood Cancer. 2004 Aug;43(2):126-33
pubmed: 15236278
Pediatr Blood Cancer. 2022 Jan;69(1):e29359
pubmed: 34520101
Eur J Cancer. 2020 Sep;136:186-194
pubmed: 32711377
Acta Oncol. 2013 Jun;52(5):987-93
pubmed: 22943385
J Clin Oncol. 2004 May 15;22(10):1934-43
pubmed: 15143087
Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):291-7
pubmed: 3403312
Neurooncol Adv. 2020 Apr 13;2(1):vdaa048
pubmed: 32642701
J Oncol Pharm Pract. 2021 Mar 27;:10781552211005533
pubmed: 33779369
Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):285-90
pubmed: 3403311
Cancer. 2005 Jun 15;103(12):2636-42
pubmed: 15861409
Lancet Oncol. 2015 Sep;16(9):e470-e477
pubmed: 26370356